| Objective(s):The clinical data of chronic heart failure patients were collected and analyzed to observe the short-term efficacy and safety of SGLT2 i in the treatment of chronic heart failure patients with two different ejection fractions.Methods: A total of 205 patients with chronic heart failure admitted to the Department of Cardiovascular Medicine,Kunming First People’s Hospital,from 2020 to 2022 were selected for the study.Patients were divided into a total of HFrEF group(n=100)and HFpEF group(n=105)according to their left ventricular ejection fraction;all study subjects were treated with a standardized chronic heart failure drug regimen,to which dapagliflozin was added as HFrEF-trial group(n=48)and HFpEF-trial group(n=55),and patients not using dapagliflozin were HFrEF-control group(n=52),and HFpEF-control group(n=50).Baseline data were collected from patients,and information related to resting heart rate,blood pressure,NYHA cardiac function classification,NT-pro BNP,LVEF,CO,LVEDD,and LVESD were collected before and after 3 months of treatment,respectively.The clinical efficacy of each group was determined according to the efficacy determination criteria.The occurrence of composite endpoint events(readmission due to heart failure or cardiovascular death)and adverse events were recorded during the 3-month follow-up.The data were analyzed using SPSS26.0 software for relevant statistical analysis to compare the changes in resting heart rate,blood pressure,NYHA cardiac function classification,NT-pro BNP,LVEF,CO,LVEDD,and LVESD;to compare the clinical efficacy and occurrence of adverse events between groups;and to plot survival curves and compare the differences in the incidence of cumulative composite endpoint events during follow-up between groups.Results:1.Statistical analysis of the baseline information of all study subjects showed that there was no statistical difference between the baseline information of patients in the HFrEF-test group and the HFrEF-control group and the HFpEF-test group and the HFpEF-control group(P > 0.05).2.Statistical analysis of the resting heart rates of all study subjects showed that the resting heart rates of patients in both the HFrEF-test group and the HFpEF-test group were lower after 3 months of treatment compared with those before treatment and the control group during the same period,and the differences were statistically significant(P < 0.05).3.Statistical analysis of the diastolic and systolic blood pressure of all study subjects showed that the diastolic blood pressure of patients in the HFrEF-test group decreased after 3 months of treatment compared with the pre-treatment and contemporaneous control groups,and the difference was statistically significant(P <0.05);after 3 months of treatment,the systolic blood pressure of patients in the HFrEF-test group,the systolic blood pressure and diastolic blood pressure of patients in the HFpEF-test group compared with before treatment and the control group during the same period were not statistically different(P > 0.05).4.Statistical analysis of NYHA cardiac function classification,NT-pro BNP,LVEF,CO,LVEDD,and LVESD of all study subjects showed that the NYHA cardiac function classification,NT-pro BNP,LVEF,CO,LVEDD,and LVESD of patients in the HFrEF-test group and HFpEF-test group after 3 months of treatment were better than those before treatment and the control group during the same period,and the difference was statistically significant(P < 0.05).5.According to the criteria for determining the efficacy,the total effective rate of patients in the HFrEF-trial group was 50.00%,and the total effective rate of patients in the HFpEF-trial group was 69.09%.After statistical analysis,the results showed that the total effective rate of patients in the HFrEF-test group and HFpEF-test group was higher than that of the control group after 3 months of treatment,and the difference was statistically significant(P < 0.05).6.Using readmission for heart failure or cardiovascular death as the composite endpoint event,the incidence of the composite endpoint event was 35.42% in the HFrEF-trial group and 25.45% in the HFpEF-trial group during the 3-month follow-up period.After statistical analysis,the results showed that the incidence of the composite endpoint event in the HFrEF-trial group and the HFpEF-trial group was lower than that in the control group during the 3-month treatment period,and the difference was statistically significant(P < 0.05).7.During the follow-up period of 3 months,a total of 37 cases of adverse reactions occurred in all study subjects,including 21 cases in the HFrEF group(12cases in the HFrEF-trial group and 9 cases in the HFrEF-control group)and 16 cases in the HFpEF group(9 cases in the HFpEF-trial group and 7 cases in the HFpEF-control group).After statistical analysis,the results showed that there was no statistically significant difference in the incidence of adverse reactions in the HFrEF and HFpEF patients in the test group compared with the control group(P > 0.05).Conclusion(s):1.SGLT2 i is effective in improving clinical symptoms and cardiac function in patients with HFrEF and HFpEF,and also reduces the risk of composite endpoint events in patients with HFrEF and HFpEF.2.SGLT2 i has demonstrated a good safety profile in the clinical application of HFrEF and HFpEF patients,and has a promising application in the field of heart failure pharmacotherapy. |
PDF Full Text Request